Skip to main content
SpringerLink
Log in

Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer

Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Patients with gastrointestinal cancer who were receiving moderately emetogenic chemotherapy (MEC) were switched from granisetron, a first-generation 5-hydroxytryptamine-3 receptor antagonist, to palonosetron at our hospital. In the present study, we compared effectiveness before and after switching antiemetic treatment.

Methods

Among patients who were receiving MEC for gastrointestinal cancer, we prospectively observed 46 patients given granisetron and 46 given palonosetron. To allow adverse reactions to be graded in accordance with the Common Terminology Criteria for Adverse Events, version 4.0, a questionnaire designed at our hospital was used to compare the occurrence of delayed nausea and vomiting between patients who received granisetron (GRA group) and those who received palonosetron (PAL group).

Results

The incidence of delayed nausea was significantly lower in the PAL group (8.7 %, 4/46; p < 0.01) than in the GRA group (37 %, 17/46). Delayed vomiting developed in five patients (10.9 %) in the GRA group, but did not occur in the PAL group. On the basis of the results of multivariate analysis, young age, female gender, and the use of granisetron were significant risk factors for delayed nausea.

Conclusion

Our survey showed that palonosetron effectively controls delayed nausea caused by MEC for gastrointestinal cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Goedhals L, Heron JF, Kleisbauer JP et al (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 9:661–666

    Article  CAS  PubMed  Google Scholar 

  2. Latreille J, Pater J, Johnston D et al (1998) Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 16:1174–1178

    CAS  PubMed  Google Scholar 

  3. The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554–1559

    Article  Google Scholar 

  4. Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 h after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294

    Article  CAS  PubMed  Google Scholar 

  5. Wong EH, Clark R, Leung E et al (1995) The interaction of RS25259-197, a potent and antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 114:851–859

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Maemondo M, Masuda N, Sekine I et al (2009) A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol 20:1860–1866

    Article  CAS  PubMed  Google Scholar 

  7. Rojas C, Stathis M, Thomas AG et al (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469–478

    Article  CAS  PubMed  Google Scholar 

  8. Rojas C, Thomas AG, Alt J et al (2010) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193–199

    Article  CAS  PubMed  Google Scholar 

  9. Saito M, Aogi K, Sekine I et al (2009) Palonosetron plus dexamethasone versus granisetoron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind double-dummy randomised comparative phase III trial. Lancet Oncol 10:115–124

    Article  CAS  PubMed  Google Scholar 

  10. Horie Y, Boku N (2012) A guideline for antimetics use for patients with malignancies. Gan To Kagaku Ryoho 39:1163–1168, Article in Japanese

    PubMed  Google Scholar 

  11. Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L, Rittenberg C, Gralla RJ (2007) Validation and psychometric properties of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool (MAT). J Pain Symptom Manag 34:148–159

    Article  Google Scholar 

  12. Botrel TE, Clark OA, Clark L et al (2011) Efficacy of palonosetron compared to other serotonin inhibitors in preventing chemotherapy-induced nausea and vomiting in patients receiving moderately or highly emetogenic treatment: systematic review and meta-analysis. Support Care Cancer 19:823–832

    Article  PubMed  Google Scholar 

  13. Roila F, Herrstedt J, Apro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy induced nausea and vomiting; results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):232–243

    Article  Google Scholar 

  14. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 26:4189–4198

    Article  Google Scholar 

  15. National Comprehensive Cancer Network: NCCN Clinical Practice Guideline in Oncology TM; Antiemesis Ver.1.2012

  16. Sepulveda-Vidosola AC, Betanzos-Cabrera Y, Lastiri GG et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39:601–606

    Article  Google Scholar 

  17. Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449

    Article  CAS  PubMed  Google Scholar 

  18. Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473–2482

    Article  CAS  PubMed  Google Scholar 

  19. Gralla R, Lichinitser M, Van Der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of double-blind randomized phase III trial comparing single-dose of palonosetron with ondansetron. Ann Oncol 14:1570–1577

    Article  CAS  PubMed  Google Scholar 

  20. Yu Z, Liu W, Wang L et al (2008) The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, randomized, double-blind parallel, comparative clinical trial. Support Care Cancer 17:99–102

    Article  PubMed  Google Scholar 

  21. Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting—two new agents. J Support Oncol 1:89–103

    CAS  PubMed  Google Scholar 

  22. Sekine I, Segawa Y, Kubota K et al (2013) Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci 104:711–717

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

We certify that we have no conflict of interest relevant to this manuscript.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Matsuyama Red Cross Hospital, Bunkyo-cho, Matsuyama-shi, Ehime, 790-8524, Japan

    Michiyasu Murakami, Hiroki Hashimoto, Kyohei Yamaguchi & Shozo Senba

  2. Department of Nursing, Matsuyama Red Cross Hospital, Bunkyo-cho, Matsuyama-shi, Ehime, 790-8524, Japan

    Ikuko Yamaguchi

  3. Department of Gastrointestinal Surgery, Matsuyama Red Cross Hospital, Bunkyo-cho, Matsuyama-shi, Ehime, 790-8524, Japan

    Takeshi Siraishi

Authors
  1. Michiyasu Murakami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroki Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kyohei Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ikuko Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shozo Senba
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takeshi Siraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michiyasu Murakami.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murakami, M., Hashimoto, H., Yamaguchi, K. et al. Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer. Support Care Cancer 22, 905–909 (2014). https://doi.org/10.1007/s00520-013-2046-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-013-2046-6

Keywords

search

Navigation